Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Merck
Moodys
Baxter
Medtronic

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

LYNPARZA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Lynparza, and when can generic versions of Lynparza launch?

Lynparza is a drug marketed by Astrazeneca Pharms and is included in two NDAs. There are eight patents protecting this drug.

This drug has two hundred and seventy-six patent family members in forty-nine countries.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olaparib profile page.

Summary for LYNPARZA
Drug patent expirations by year for LYNPARZA
Drug Prices for LYNPARZA

See drug prices for LYNPARZA

Generic Entry Opportunity Date for LYNPARZA
Generic Entry Dates for LYNPARZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for LYNPARZA*:
Constraining patent/regulatory exclusivity:
MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LYNPARZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Centre Georges Francois LeclercPhase 2
Thomas Jefferson UniversityPhase 1
Hospices Civils de LyonPhase 2

See all LYNPARZA clinical trials

Pharmacology for LYNPARZA
Synonyms for LYNPARZA
(2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-
09L
1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1
1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-
1021843-02-6
4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one
4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one
4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one
4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One
4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluoro-phenyl]methyl]-2H-phthalazin-1-one
4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-2H-phthalazin-1-one
4CA-0938
763113-22-0
894104-70-2
937799-91-2
A9666
AB0009952
AB1009702
ABP000423
AC-7939
ACN-032229
Acylpiperazine analogue, 47
AJ-101717
AKOS005145764
AN-493
AN-5279
ANW-43329
AOB1085
API0024518
AX8162101
AZ2281
AZD 2281
AZD 2281|||KU 0059436|||KU 59436
AZD-2281
AZD-2281 (Olaparib)
AZD2281
AZD2281,Olaparib, KU-0059436
AZD2281(olaparib)
AZD2281(olaparib)/AZD-2281/KU0059436
BB 0260909
BC245405
BCP01872
BCP9000363
BCPP000360
BDBM27566
BR-40514
BRD-K02113016-001-08-9
BRD-K02113016-001-09-7
cc-16
CHEBI:83766
CHEMBL521686
CS-0075
CTK8B3857
D09730
DB09074
EN002690
EX-7210
EX-A002
FDLYAMZZIXQODN-UHFFFAOYSA-N
FT-0083489
FT-0651458
GP0126
GTPL7519
HMS3654G13
HY-10162
I06-2362
J-503540
KS-00000HXY
KU-0059436
KU-59436
KU0059436
KU59436
Lynparza (TN)
MFCD13185161
MFCD13185161 (95%)
MLS006010185
MolPort-009-679-395
NCGC00238451-01
NCGC00238451-02
NCGC00238451-09
NSC-747856
NSC747856
Olaparib
Olaparib - AZD2281
Olaparib (AZD2281, Ku-0059436)
Olaparib (AZD2281, KU0059436)
Olaparib (AZD2281)
Olaparib (JAN/USAN/INN)
Olaparib [USAN:INN]
OLAPARIB cpd
Olaparib; KU 0059436
Olaparibum
PubChem19148
QC-2660
RL04905
S-3781
S-7836
s1060
SB14617
SC-65060
SCHEMBL426568
SMR004701291
SS-4573
SW218142-2
SY040527
UNII-WOH1JD9AR8
WOH1JD9AR8
Z-3275
ZINC40430143

US Patents and Regulatory Information for LYNPARZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for LYNPARZA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1633724 1590019-4 Sweden   Start Trial PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
1633724 S1500012 Hungary   Start Trial PRODUCT NAME: OLAPARIB
1633724 C 2015 011 Romania   Start Trial PRODUCT NAME: OLAPARIB; NATIONAL AUTHORISATION NUMBER: EU/1/14/959/001; DATE OF NATIONAL AUTHORISATION: 20141216; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/959/001; DATE OF FIRST AUTHORISATION IN EEA: 20141216
1633724 15C0022 France   Start Trial PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218
1633724 CR 2015 00012 Denmark   Start Trial PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216
1633724 92680 Luxembourg   Start Trial PRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKesson
Dow
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.